Sirolimus inhaled (OrphAI Therapeutics)

西罗莫司吸入剂 (OrphAI Therapeutics)

Report date: 2026/05/23 20:00:57

Base Information

Drug NameSirolimus inhaled (OrphAI Therapeutics)
Drug Alias NameLAM-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMammalian target of Rapamycin (mTORC1) inhibitorsmTOR Complex 2 inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsRejection of lung transplantationBronchiolitis Obliterans
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOrphAI Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesOrphAI Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRejection of lung transplantationBronchiolitis Obliterans
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A